● Recruiting

Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)

Condition: Hepatocellular Carcinoma · Sponsor: National Cancer Institute, Naples

PhaseN/A

Planned participants70

Who can joinAll sexes, 18 Years to 100 Years

Healthy volunteersNo

About this study

Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: From Benchside to Bedside (HepAnt) - Study of the Role of the Metagenome in Head and Neck Tumors Using Omics Techniques (HeNomics).

This description comes directly from the study's public registry record.

Talk to the study team

Luigi Buonaguro, DR · 08117770587 · l.buonaguro@istitutotumori.na.it

Always discuss trial participation with your own doctor first.

Locations (1)

Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale

Naples, Italy

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06905262